Exploring QuidelOrtho (QDEL) Valuation as Shares Decline 6% to Close at $29.98

QuidelOrtho (QDEL) shares have slipped over the past week, trading 6% lower on the day to close at $29.98. The stock remains down about 33% so far this year, raising questions about its future trajectory.

See our latest analysis for QuidelOrtho.

QuidelOrtho’s share price has lost ground this year, and momentum continues to fade following a rough 12 months. The company’s total shareholder return is down over 31% for the year and nearly 57% over three years, highlighting just how challenging the environment has been despite moments of optimism among medtech peers.

While QuidelOrtho faces its own hurdles, investors who want to see what else is out there in the healthcare space can check out See the full list for free.

With shares trading well below analyst price targets and mixed signals from recent financials, investors are left to wonder if QuidelOrtho is a hidden value play or if the market has already accounted for all its future growth.

Most Popular Narrative: 25.7% Undervalued

Compared to the last close of $29.98, the most widely followed narrative assigns QuidelOrtho a fair value over 25% higher. This large gap signals a belief among analysts that the company’s fundamentals and outlook justify a price well above current levels. Key assumptions drive a bullish case for recovery and growth.

Expansion into international markets such as Latin America, Asia Pacific, and underpenetrated regions like China, where differentiated technology, low market share, and a large runway for immunoassay growth exist, positions QuidelOrtho to capture increased demand stemming from global health system focus on early detection and public health surveillance, which should drive topline revenue growth.

Read the complete narrative.

Want to know exactly what future growth is baked into this price target? The numbers behind this bullish valuation hinge on ambitious revenue and margin projections. Ready to see which financial assumptions make up the engine for this upgrade? Click through to find the quantitative backbone behind the valuation.

Result: Fair Value of $40.33 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, persistent declines in COVID-related revenue and portfolio discontinuations could undermine QuidelOrtho’s turnaround story if no new growth drivers emerge.

Find out about the key risks to this QuidelOrtho narrative.

Build Your Own QuidelOrtho Narrative

If you see things differently or prefer analyzing the numbers your own way, you can shape your own outlook in just a few minutes. Do it your way

A great starting point for your QuidelOrtho research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.

Looking for More Investment Ideas?

Smart investors look beyond a single name to seize tomorrow’s biggest opportunities. Don’t let great stocks slip by. Choose your next move with confidence using these curated ideas:

• Uncover high-yield options and build a stream of potential passive income by checking out these 19 dividend stocks with yields > 3%.
• Catch the momentum in AI innovation and see which companies could benefit most via these 24 AI penny stocks.
• Target stocks that the market may be undervaluing right now and seize growth before it hits the mainstream through these 885 undervalued stocks based on cash flows.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com